Resource Summary Report

Generated by NIF on Sep 12, 2026

MOLM-13

RRID:CVCL_2119
Type: Cell Line

Proper Citation

RRID:CVCL_2119

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2119

Proper Citation: RRID:CVCL_2119

Description: Cell line MOLM-13 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult acute monocytic leukemia

Defining Citation: PMID:9305600, PMID:10233379, PMID:10637496, PMID:10739008, PMID:11226526, PMID:12529668, PMID:14504097, PMID:14671638, PMID:15381384, PMID:16408098, PMID:22354205, PMID:22460905, PMID:23955599, PMID:25877200, PMID:25984343, PMID:27397505, PMID:27750403, PMID:28052028, PMID:28109323, PMID:28196595, PMID:29491412, PMID:30285677, PMID:30629668, PMID:30894373, PMID:31068700, PMID:31160637, PMID:31978347, PMID:33669837, PMID:35839778, PMID:36982453

Comments: Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MOLM-13

Synonyms: MOLM13, Molm13, Molm 13

Cross References: BTO:BTO_0004175, CLO:CLO_0009848, EFO:EFO_0022694, AddexBio:C0003003/60, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722,

BioGRID_ORCS_Cell_line:403, BioSample:SAMN03473102, BioSample:SAMN10988379, cancercelllines:CVCL_2119, Cell_Model_Passport:SIDM00437, ChEMBL-Cells:CHEMBL3706573, ChEMBL-Targets:CHEMBL3706572, Cosmic:787417, Cosmic:947367, Cosmic:975274, Cosmic:996319, Cosmic:998754, Cosmic:999722, Cosmic:999772, Cosmic:1012095, Cosmic:1037671, Cosmic:1078734, Cosmic:1150897, Cosmic:1152711, Cosmic:1187863, Cosmic:1197930, Cosmic:1278778, Cosmic:1281332, Cosmic:1308222, Cosmic:1465952, Cosmic:1696139, Cosmic:1741687, Cosmic:2089664, Cosmic:2131546, Cosmic:2306220, Cosmic:2750864, Cosmic:2842299, Cosmic-CLP:1330947, DepMap:ACH-000362, DSMZ:ACC-554, DSMZCellDive:ACC-554, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:1330947, GEO:GSM482509, GEO:GSM887329, GEO:GSM888405, GEO:GSM1374688, GEO:GSM1374689, GEO:GSM1446738, GEO:GSM1670124, GEO:GSM2124117, GEO:GSM2716691, GEO:GSM2716692, GEO:GSM2716748, GEO:GSM2716749, GEO:GSM2716750, GEO:GSM2716751, IARC_TP53:30123, JCRB:JCRB1810, LiGeA:CCLE_282, LINCS_LDP:LCL-1061, PharmacoDB:MOLM13_950_2019, PRIDE:PXD030304, Progenetix:CVCL_2119, PubChem_Cell_line:CVCL_2119, Wikidata:Q54906320

ID: CVCL_2119

Record Creation Time: 20220427T220816+0000

Record Last Update: 20260913T004916+0000

Ratings and Alerts

No rating or validation information has been found for MOLM-13.

No alerts have been found for MOLM-13.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 422 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Chen TQ, et al. (2026) RBM15B recognizes H3K79me2 to guide selective m6A-modification of mRNA and enhance oncoprotein translation in MLL-r leukemia. The EMBO journal, 45(5), 1672.

Zhao S, et al. (2026) RNF25 confers mRNA damage tolerance by curbing activation of the integrated stress response. Molecular cell, 86(7), 1275.

López-Hernández L, et al. (2026) BCLAF1 links RNA splicing to ATF4-dependent metabolic adaptation in acute myeloid leukemia. bioRxiv : the preprint server for biology.

Clayfield L, et al. (2026) Retinal determination network reactivation drives chemoresistance and blocks myeloid differentiation in acute myeloid leukemia. Cell reports, 45(2), 116875.

Cao Z, et al. (2026) CRISPR-based functional genomics for dissecting therapeutic dependency in primary acute myeloid leukemia samples. Molecular cell, 86(5), 968.

Kunzmann GB, et al. (2026) Dynamic UFMylation governs cellular fitness by coordinating multi-organelle proteostasis. bioRxiv : the preprint server for biology.

Eriksson J, et al. (2026) Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia. Cancer research, 86(7), 1724.

Wu S, et al. (2026) Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine. Molecular oncology, 20(2), 555.

Lewis AC, et al. (2026) Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia. Cell, 189(1), 215.

Saad J, et al. (2026) Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia. Molecular oncology, 20(2), 389.

Tripathi C, et al. (2026) Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity. Cancer research communications, 6(3), 528.

Chung J, et al. (2026) Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity. Science (New York, N.Y.), 392(6794), eady5196.

Waclawiczek A, et al. (2026) Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. Cell stem cell, 33(6), 982.

Pereira-Martins DA, et al. (2026) ?Np73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. Cell reports. Medicine, 102540.

Su M, et al. (2026) FASN inactivation-induced progranulin (GRN) expression promotes lysosome-dependent cell death to suppress leukemogenesis. Cell reports, 45(3), 117042.

Sonowal H, et al. (2025) Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia. Cancer research communications, 5(1), 74.

Yuan Y, et al. (2025) CircTADA2A inhibits cell proliferation and promotes ferroptosis by sponging miR-638 in acute myeloid leukemia. Human cell, 38(5), 123.

Kim Y, et al. (2025) Nanopore direct RNA sequencing of human transcriptomes reveals the complexity of mRNA modifications and crosstalk between regulatory features. Cell genomics, 5(6), 100872.

Fiskus W, et al. (2025) Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. Blood cancer journal, 15(1), 40.

Shang K, et al. (2025) CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models. Cell reports. Medicine, 6(6), 102148.